Flat quarter with no financial surprises and pipeline milestones reaffirmed. The stock's 75% win rate on prior neutral calls suggests limited near-term catalyst. Traders should watch for the MAIA-ovarian interim analysis by Q1 2027 and any rilvegostomig data readouts at ASCO 2026 as the next potential inflection points. No immediate trading trigger from this filing.
Price Chart
Executive Summary
Compugen reported Q1 2026 results with revenue of $2.2M (vs $2.3M in Q1 2025) and net loss of $7.7M ($0.08/share) vs $7.2M ($0.08/share) in the prior year. Cash and equivalents stood at $134.9M with runway into 2029. Clinical milestones remain on schedule: COM701 MAIA-ovarian interim analysis by Q1 2027, AstraZeneca advancing rilvegostomig across 11 Phase 3 trials, and Gilead-partnered GS-0321 Phase 1 progressing. The filing is a routine quarterly update with no-surprise update with no material financial deviation from the prior period.
Key Facts
- Q1 2026 revenue $2.2M vs $2.3M in Q1 2025 — essentially flat with a slight decline
- Net loss $7.7M ($0.08/shr) vs $7.2M ($0.08/shr) in Q1 2025 — slightly wider loss, EPS unchanged
- Cash, equivalents, short-term deposits, and marketable securities of $134.9M as of March 31, 2026
- Cash runway expected to fund operations into 2029 with no debt
- R&D expenses increased to $6.9M from $5.8M YoY driven by clinical costs for MAIA-ovarian trial
- COM701 MAIA-ovarian trial actively enrolling; interim PFS analysis on track by Q1 2027
- AstraZeneca advancing rilvegostomig in 11 ongoing Phase 3 trials; new data to be released at ASCO 2026
- Gilead-partnered GS-0321 Phase 1 trial progressing as planned
- as per plan
Financial Impact
Revenue essentially flat (-4.7.8% QoQ from the $1.1M prior?) — but compared to prior year $2.3M revenue is ~$0.1M lower. Net loss widened by $0.5M. Cash burn of ~$7.7M per quarter implies ~2.7 years of runway. No debt. No material deviation from prior disclosed pipeline milestones.
Risk Factors
- Revenue remains de minimis and dependent on milestone-based from Gilead &&dependent on partner milestones — no core product revenue yet )
- Operating loss widening from higher R&D spend without commensurate revenue growth
- Clinical trial risks: MAIA-ovarian may fail interim analysis; partner programs could be deprioritized
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002750 |
| Document: zk2635352.htm | 0001178913-26-002750 |
| Document: 0001178913-26-002750-index-headers.html | 0001178913-26-002750 |
| Document: 0001178913-26-002750-index.html | 0001178913-26-002750 |
| Document: 0001178913-26-002750.txt | 0001178913-26-002750 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 8w ago | 6-K | $2.38 $2.56 | ▲ +7.56% | ▲ +6.33% | $2.31 (−2.94%) |
Aug 3, 2026 8w ago | 6-K | $2.38 $2.56 | ▲ +7.56% | ▲ +6.33% | $2.31 (−2.94%) |
Jun 9, 2026 16w ago | EFFECT | $2.02 $2.39 | ▲ +18.32% | ▲ +16.87% | $2.31 (+14.36%) |
May 18, 2026 19w ago | 6-K | $2.86 $2.03 | ▼ −29.02% | ▼ −30.60% | $2.31 (−19.23%) |
Apr 24, 2026 23w ago | Insider Cluster | $3.10 $2.61 | ▼ −15.81% | ▼ −19.83% | $2.31 (−25.48%) |
Apr 14, 2026 24w ago | Insider Cluster | $2.88 $2.87 | ▼ −0.35% | ▼ −6.64% | $2.31 (−19.79%) |
Apr 13, 2026 24w ago | 144 | $2.76 $2.87 | ▲ +3.99% | ▼ −3.74% | $2.31 (−16.30%) |
Mar 26, 2026 27w ago | Insider Cluster | $2.06 $3.10 | ▲ +50.49% | ▲ +39.82% | $2.31 (+12.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access